VANCOUVER, British Columbia, June 30, 2025 ( GLOBE NEWSWIRE ) -- Rakovina Therapeutics Inc. ( "Rakovina" or the "Company" ) ( TSX-V: RKV ) ( FSE: 7JO0 ) , a biopharmaceutical company advancing next-generation cancer therapies through artificial intelligence ( AI ) -powered drug discovery, today ...

Over the weekend, Yun-Ta Tsai, a former Nokia Telecommunications NOK researcher and current Tesla Inc. TSLA senior staff engineer, shared his perspective on Apple Inc.'s AAPL slow adoption of artificial intelligence ( AI ) and autonomous vehicles.

The S&P 500 hit record highs on Friday as prominent investment manager Dan Niles advised investors to temporarily ignore traditional valuation metrics while positioning for continued market gains through the second-quarter earnings season.

Ad hoc announcement pursuant to Art. 53 LR ...

Riliprubart granted orphan drug designation in Japan for chronic inflammatory demyelinating polyneuropathy Two phase 3 studies are currently underway testing riliprubart in people with CIDP as a potential first-in-class treatment

Geneva, Switzerland, June 30, 2025 ( GLOBE NEWSWIRE ) -- SEALSQ Corp ( NASDAQ: LAES ) ( "SEALSQ" or "Company" ) , a company that focuses on developing and selling Semiconductors, PKI, and Post-Quantum technology hardware and software products, today announced the completion of its strategic ...

Phase 1b study supports proof-of-concept in DOK7 congenital myasthenic syndromes Decision informed by favorable safety profile and consistent functional improvement over time across multiple efficacy measures

Geneva, Switzerland - June 30, 2025 - STALICLA SA, a Geneva-based clinical-stage biotech company pioneering precision medicine for neurodevelopmental and neuropsychiatric disorders, today announced the successful closing of a CHF 2 million financing led by Addex Therapeutics.

Ad Hoc Announcement Pursuant to Art. 53 LR ...

Riliprubart granted orphan drug designation in Japan for chronic inflammatory demyelinating polyneuropathy ...